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Abstract
Gastric cancer currently ranks fourth in cancer-related 
mortality worldwide. In the western world, it is most 
often diagnosed at an advanced stage, after becoming 
metastatic at distant sites. Patients with advanced 
disease (locally advanced or metastatic) have a somber 
prognosis, with a median overall survival of 10-12 
mo, and palliative chemotherapy is the mainstay of 
treatment. In recent years, novel approaches using 
inhibition of human epidermal growth factor receptor 
2 (HER2) have demonstrated significant improvements 
in progression-free and overall survival, compared 
with chemotherapy alone, in first-line treatment of 
patients with overexpression of HER2. In addition, 
both second-line chemotherapy and treatment with the 
vascular endothelial growth factor receptor-inhibitor 
ramucirumab demonstrated significant benefits in terms 
of overall survival, compared with best supportive 
care, in randomized studies. Moreover, ramucirumab in 
combination with chemotherapy demonstrated further 
significant benefits in terms of progression-free and 
overall survival, compared with chemotherapy alone, in 
second-line treatment for patients with metastatic gastric 
cancer. A recently published molecular classification 
of gastric cancer is expected to improve patient 
stratification and selection for clinical trials and provide 
a roadmap for future drug development. Nevertheless, 
despite these developments the prognosis of patients 
with advanced gastric cancer remains poor. In this 
review we discuss current standards of care and outline 
major topics of drug development in gastric cancer.
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Core tip: With the integration of both ramucirumab and 
transtuzumab, treatment options for advanced gastric 
cancer have increased significantly in recent years. 
Therefore, a reconsideration of treatment options 
and results for gastric cancer is necessary. This paper 
discusses results of phase Ⅲ trials for both standard 
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chemotherapy and targeted treatments in metastatic 
gastric cancer. Furthermore, results of selected early-
phase clinical trials, for example on immune checkpoint 
inhibitors, are discussed.
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INTRODUCTION
Gastric cancer (GC) currently ranks fourth in cancer 
incidence worldwide and is the most common type 
of cancer among Japanese men[1,2]. In the last few 
decades, epidemiological changes in the anatomical 
distribution have converged with a decline in the 
incidence of distal (non-cardia) GC, notably in 
developed countries, and an increase in the incidence 
of adenocarcinoma of the proximal stomach. The 
origins of these changes are probably multifactorial 
and linked to many risk factors, including Helicobacter 
pylori (H. pylori) infection incidence, dietary factors, 
and obesity[3].
GC has a routine appearance of adenocarcinoma in 
90% of cases and is divided into intestinal and diffuse 
types according to the Lauren classification[4]. The 
intestinal type is associated with H. pylori infection 
and dysplastic changes, whereas the diffuse type 
is characterized by sheets of cells without gland 
formation and occasionally signet ring cells[5]. Diffuse-
type GC can also be associated with H. pylori infection, 
but not with intestinal metaplasia, as a precursor and 
is known to have a poorer prognosis.
Several attempts have been made to develop 
a molecular classification of GC based on genomic 
alterations. In 2012, Deng et al[6] identified 5 
subgroups of GC defined by signature genomic 
alterations: FGFR-2 (9% of tumors), KRAS (9%), EGFR 
(8%), ERBB-2 (7%) and MET (4%). Interestingly, 
about 37% of GC had genomic alterations in the 
receptor of the tyrosine kinase RAS. 
Recently, the Cancer Genome Atlas Research 
Network identified four molecular subtypes of GC 
by analyzing data from 295 primary tumors in 
six molecular platforms: (1) EBV-infected tumors 
(9%); (2) microsatellite unstable tumors (22%); 
(3) genomically stable tumors (20%); and (4) 
chromosomally unstable tumors (50%). The resear-
chers confirmed that every subtype has distinct 
genomic features. For example, EBV-infected tumors 
frequently contain mutations in the PIK3CA gene (80% 
vs 3%-42% in the other subtypes), amplifications of 
the JAK2 gene, and elevated expression of PD-L1. In 
this context, PIK3CA inhibitors and PD-L1 antagonists 
merit further investigation[7]. 
Tumors classified as chromosomally unstable 
are predominantly localized at the cardia or the 
gastrointestinal junction. This subtype is enriched 
for TP53 mutations and RTK-RAS activation. The 
microsatellite unstable subtype accounts for 22% of 
GC cases and is significantly associated with MLH1 
silencing and genomic hypermutation. Moreover, the 
vascular endothelial growth factor A (VEGFA) gene 
is amplified in this subtype, suggesting that it may 
respond to anti-angiogenic therapy. Finally, the fourth 
subtype, the “genomically stable”, is histologically 
associated with diffuse-type cancer, as well as CDH1 
and RHOA mutations. 
Despite these major advances in our understanding 
of the biology of GC, the median survival rate of 
patients with advanced GC is still less than 12 mo, 
and the development of personalized treatment 
strategies is the principal challenge. The primary aim 
of this review is to summarize data from recent phase 
Ⅲ clinical trials on both chemotherapy and targeted 
therapies in advanced GC and to discuss their impact 
on current clinical practice. Furthermore, we discuss 
recent phase Ⅱ trials of special interest. 
FIRST-LINE TREATMENT
Before any systemic treatment for GC is initiated, the 
status of the human epidermal growth factor receptor 
2 (HER2) is determined. Treatment options for the 
approximately 20% of patients with HER2-positive GC 
are discussed in the paragraph on targeted therapies. 
The following section discusses the treatment options 
for patients with HER2-negative GC. 
Chemotherapy is the standard first-line treatment 
for patients with advanced GC and a good performance 
status. Available data from randomized clinical 
trials clearly demonstrate a statistically significant 
advantage of palliative chemotherapy, compared with 
best supportive care (BSC), in terms of palliation of 
symptoms and improvement of survival for patients 
with advanced GC[8]. 
In contrast, the benefit of combination - compared 
with single-agent - chemotherapy is much smaller: 
A meta-analysis published in 2010 indicated a 
modest survival benefit (approximately 1.5 mo) 
for combination chemotherapy over single-agent 
chemotherapy. Of note, the combination chemotherapy 
regimens included in this analysis were mostly “older” 
regimens (combination of 5-FU/anthracyclines) and 
therefore might not have had optimal efficacy[9]. For 
example, in the Japanese phase Ⅲ “SPIRITS” trial, 305 
patients were randomly assigned to S-1 (40-60 mg/m2 
twice-daily on days 1-21 and cisplatin 60 mg/m2 on 
day 8 every 5 wk) or S-1 alone (40-60 mg/m2 twice-
daily on days 1-28 every 6 wk). Both progression-free 
survival (PFS) (6 vs 4 mo) and overall survival (OS) (13 
mo vs 11 mo, HR = 0.77; 95%CI: 0.61-0.98) were 
significantly improved by the combination regimen[10]. 
However, the Japanese phase Ⅲ JCOG 9912 trial, 
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which compared a continuous infusion of 5-FU (800 
mg/m2 per day on days 1-5 every 4 wk) with the 
combination of intravenous irinotecan (70 mg/m2 
per day on days 1 and 15) and cisplatin (80 mg/m2 
on day 1) every 4 wk and with oral S-1 alone (40 
mg/m2 twice-daily on days 1-28 every 6 wk), did not 
confirm the superiority of this combination. While S-1 
alone was non-inferior to 5-FU, patients receiving the 
combination of irinotecan plus cisplatin did not have a 
survival improvement as compared to the treatment 
with S-1 alone[11]. 
More than 50 years since its development, infusional 
5-FU remains the backbone of most combination 
chemotherapy regimens in advanced GC. However, in 
recent years, two oral fluoropyrimidines - capecitabine 
and S-1 - were shown to be at least equal in efficacy 
to 5-FU. Capecitabine was shown to be non-inferior in 
two phase Ⅲ trials. 
Kang et al[12] conducted a randomized phase Ⅲ 
trial comparing cisplatin (80 mg/m2 on day 1) plus 
capecitabine (1000 mg/m2 twice-daily on days 1-14) in 
a 21-d cycle to cisplatin plus 5-FU (800 mg/m2 per day 
as a continuous infusion on days 1-5). The trial met its 
primary endpoint and demonstrated the non-inferiority 
of cisplatin plus capecitabine, compared with cisplatin 
plus 5-FU. Although patients receiving capecitabine 
had a better response rate (RR) than those receiving 
5-FU (41% vs 29%), PFS, RRs, and toxicity profiles 
were similar.
The oral fluoropyrimidine S-1 is a widely accepted 
treatment option, as a single agent or in combination 
chemotherapy, for advanced GC in Japan. S-1 is a 
combination of tegafur with two enzyme inhibitors: 
5-chloro-2,4-dihydroxypyridine (CDHP), a reversible 
inhibitor of dihydropyrimidine dehydrogenase, and 
potassium oxonate (Oxo). CDHP enhances the 
anticancer activity of tegafur by increasing its half-
life, and Oxo reduces the gastrointestinal toxicity of 
tegafur. Because CYP2A6, which converts tegafur to 
5-FU, is highly active in Caucasians, separate studies 
in Caucasian populations were necessary before 
registration of S-1 in Europe and the United States.
The pivotal trial, which evaluated S-1 in a Western 
population, is the randomized phase Ⅲ “FLAGS” trial. 
This trial compared a regimen of cisplatin (75 mg/m2 
on day 1) plus S-1 (25 mg/m2 twice-daily on days 1-21) 
with cisplatin (100 mg/m2 on day 1) plus 5-FU (1000 
mg/m2 per day for 5 d) over a 28-d cycle. Although the 
comparison of the two fluoropyrimidines in this trial is 
limited by the different doses of cisplatin, the cisplatin/
S-1 combination was as effective as the cisplatin/5-FU 
combination (OS 8.6 mo vs 7.9 mo for S-1 vs 5-FU). 
Importantly, patients receiving 5-FU experienced 
significantly more side effects than did patients treated 
with S-1: rates of grade 3/4 neutropenia were 32.3% 
vs 63.6%, rates of complicated neutropenia were 
5.0% vs 14.4%, and rates of stomatitis were 1.3% vs 
13.6%[13].
Platinum derivatives - alternatives to cisplatin
Several recent studies explored whether oxaliplatin 
can replace cisplatin for GC. Cisplatin-free regimens 
represent a more convenient therapeutic approach, 
which avoids the necessary hyperhydration and 
decreases the risk of renal and ototoxicity associated 
with cisplatin, but at the price of increased neurotoxicity. 
Two phase Ⅲ trials demonstrated a non-inferiority of 
oxaliplatin, compared with cisplatin, in the treatment 
of advanced GC, and a third trial observed comparable 
results.
In a randomized phase Ⅲ study conducted in 
Japan, the standard SP regimen (S-1 40 mg/m2 twice-
daily on days 1-21 and cisplatin 60 mg/m2 on day 8 
for 5 wk) was compared to SOX (S-1 40 mg/m2 twice-
daily on days 1-14 and oxaliplatin 100 mg/m2 on day 
1 for 3 wk). A total of 685 patients participated in the 
study, which reached its primary endpoint by showing 
a non-inferiority of SOX in PFS. As expected, serious 
adverse events occurred more often in the patients 
treated with SP (29.3% vs 37.9%). Furthermore, the 
rate of treatment-related deaths was twice as high in 
the patients treated with SP (2.4% vs 1.2%)[14]. 
Al-Batran et al[15] compared biweekly infusional 
fluorouracil and leucovorin, either in combination 
with oxaliplatin (FLO) or cisplatin (FLP). This trial 
confirmed the better tolerability of oxaliplatin. While 
median OS (10.7 mo vs 8.8 mo) showed no significant 
differences between the two groups, a trend towards 
better PFS was observed in the patients treated with 
FLO. However, as expected, the rates of peripheral 
neuropathy were significantly higher in the patients 
treated with FLO (63% vs 22%). Interestingly, a 
subgroup analysis of patients older than 65 years 
indicated that FLO exhibited a significantly superior RR 
and OS (13.9 mo vs 7.2 mo), forming the basis for the 
widespread use of this combination in elderly patients. 
In the landmark REAL-2 trial, patients were 
randomized into four groups [epirubicin, oxaliplatin 
and capecitabine (EOX); epirubicin, oxaliplatin and 
5-FU (EOF); epirubicin, cisplatin and 5-FU (ECF); 
and epirubicin, cisplatin and capecitabine (ECX)] in a 
two-by-two factorial design. The results of this trial 
confirmed that oxaliplatin was non-inferior to cisplatin 
in combination with epirubicin and either 5-FU or 
capecitabine. Furthermore, apart from the expected 
differences in toxicities between the two agents, fewer 
thromboembolic events (7.6% vs 15%) were observed 
in the patients treated with oxaliplatin, compared with 
cisplatin[16].
Irinotecan is another alternative to platinum 
derivatives that has been evaluated in several 
randomized trials. In 2008, Dank et al[17] published 
the results of a phase Ⅲ trial comparing irinotecan/5-
FU to cisplatin/5-FU. Although irinotecan/5-FU did not 
show an improvement in time-to-progression, the 
combination was better tolerated, as a lower rate of 
patients discontinued treatment due to toxicity (10% 
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whether 5-FU can be replaced by capecitabine in a three-
drug regimen including docetaxel and oxaliplatin[22]. The 
patients treated with the combination of docetaxel, 
oxaliplatin and 5-FU (TEF) had a significantly better OS 
(14.6 mo vs 11.3 mo), PRS (7.6 mo vs 5.5 mo) and 
RR (46.6% vs 25.6%) compared with the docetaxel, 
oxaliplatin and capecitabine group (TEX). Furthermore, 
the TEF regimen was associated with a better toxicity 
profile.
Is triplet superior to doublet chemotherapy in advanced 
GC? 
When discussing triplet vs doublet chemotherapy 
regimens, we need to address the regimens, the 
outcomes and the patients. 
Regarding the regimens: a superiority in terms of 
survival for 5-FU, an anthracycline and cisplatin (ECF) 
over the same regimens without the anthracycline 
or cisplatin was demonstrated in our meta-analyses 
published in 2006 and 2010[8,9]. However, those trials 
were conducted more than 10 years ago, when second-
line therapy was not generally available. At present, 
second-line treatment is routinely administered: up 
to 50% of patients in European studies[23,24] and 80% 
of patients in Asian trials are treated with second-
line chemotherapy. The recently published phase Ⅲ 
trial by Guimbaud et al[23], which compared the three-
drug regimen of ECX in first line to FOLFIRI vs the 
reverse sequence, did not observe a survival benefit 
for patients treated with ECX, compared with FOLFIRI. 
Furthermore, there were no differences in quality-
of-life between study arms, and FOLFIRI was better 
tolerated. Other triplet chemotherapy regimens, such 
as DCF and FLOT, which were discussed previously, 
have not demonstrated convincing benefits in terms 
of survival, but instead increased toxicity rates. 
Therefore, these regimens are not generally accepted 
as standards of care. Results for other outcomes, 
such as quality-of-life, were contradictory for different 
regimens: whereas treatment with DCF resulted in a 
significant delay in the deterioration of quality-of-life, 
compared with CF, a higher rate of patients treated 
with FLOT (47.5%), as compared to FLO (20.5%) 
experienced a > 10 point deterioration of quality-of-life 
global health scores after 8 wk of treatment[24,25].
The question whether subgroups, such as patients 
with locally advanced or limited metastatic disease, 
may have a benefit from these combinations, is 
currently under investigation.
Second-line and beyond: As much as for first-
line treatment, the aim of second and later lines of 
treatment in advanced GC is to increase survival and 
control the clinical symptoms of the disease, with 
as little toxicity as possible and no negative impact 
on quality-of-life. Several phase Ⅲ clinical trials and 
a recent meta-analysis demonstrated a modest but 
significant survival benefit of chemotherapy in this 
vs 22%). This observation has been confirmed in other 
randomized phase Ⅱ trials[18]. 
For these reasons both oxaliplatin and irinotecan 
are adequate substitutes for cisplatin in combination 
with fluoropyrimidines.
What is the role of taxanes in GC? 
In the V-325 study, published by Van Cutsem et al[19], 
445 patients were treated with cisplatin/5-FU with 
or without docetaxel as a first-line therapy. Although 
the RR (37% vs 25%), time-to-progression (5.6 mo 
vs 3.7 mo) and 2-year OS rate (18% vs 9%) were 
improved by the addition of docetaxel, the absolute 
benefit in terms of survival was less than 4 wk, and 
was counterbalanced by a significant increase in grade 
3-4 adverse events. 
In view of the significant toxicities associated with 
this regimen, especially in the elderly population, 
several “modified DCF” regimens have been developed. 
One example is FLOT (docetaxel 50 mg/m2, infusional 
5-FU 2600 mg/m2, leucovorin 200 mg/m2, oxaliplatin 
85 mg/m2) every 2 wk. A randomized phase Ⅱ study 
(n = 143) by Al-Batran et al[15] specifically addressed 
the question whether the addition of docetaxel to 
the combination of FLO is feasible in fit patients older 
than 65 years. Significantly more grade 1-4 adverse 
events such as neutropenia, alopecia and diarrhea 
were observed in the FLOT group, but there were no 
differences between the two groups in terms of serious 
adverse events, discontinuation for toxicity or toxicity-
related deaths[20]. Thus, the FLOT regimen was feasible 
in the selected fit elderly patients. However, quality-of-
life was decreased in the patients treated with FLOT, 
compared with the patients treated with FLO. Although 
the FLOT group demonstrated an improved RR (49% 
vs 28%) and a trend towards a better PFS (9.0 mo vs 
7.1 mo, P = 0.79), there was no significant benefit in 
median OS (17.3 mo vs 14.5 mo, P = 0.39). For this 
reason, the authors concluded that “this study confirms 
the role of the doublet combination FLO as a tolerable 
and active treatment option for older adult patients 
with metastatic gastric cancer”. Interestingly, subgroup 
analyses indicated that patients with locally advanced 
(non-metastatic) tumors and patients younger than 70 
years benefited more from FLOT than FLO. However, 
this result needs prospective confirmation in further 
trials. 
The phase Ⅲ “START” trial, which compared S1/
docetaxel (S-1 at 80-120 mg/d on days 1-14 of a 21-d 
cycle with docetaxel 40 mg/m2 every 21 d) vs S-1 
alone (days 1-28 of a 42-d cycle) in 635 Japanese and 
Korean patients, showed a significant benefit in terms 
of PFS (5.3 mo vs 4.2 mo) and OS (12.5 vs 10.8 
mo) in favor of the combination. While the RR in the 
combination group was 38.8% (26.8% in the single-
agent group), 58% of the patients presented at least 
one grade 3 toxicity in the combination group[21]. 
Another recent randomized phase Ⅱ trial addressed 
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setting for patients with good performance status[26,27]. 
Single-agent therapy with irinotecan or taxanes have 
been shown to be effective. Therefore, the choice of 
the regimen should be guided by the previous lines 
of therapy and eventual residual toxicities (e.g., 
neurotoxicity). 
In a German (AIO) phase Ⅲ study containing 
patients with advanced GC and a performance status 
of 0-2 who had failed first-line treatment, irinotecan 
(250 mg/m2 on day 1 of a 21-d cycle, to be increased 
to 350 mg/m2 based on tolerance) showed a significant 
benefit in terms of OS (4 mo vs 2.4 mo, P = 0.012) 
and RR (44% vs 5%), compared with BSC. Although 
the study was closed due to poor accrual after 
inclusion of 40 patients, a significant improvement 
in tumor-related symptoms was noted in 50% of the 
patients treated with irinotecan, compared with 7% of 
the patients treated with BSC[28].
The survival benefit of second-line or third-line 
chemotherapy was confirmed in a Korean phase Ⅲ trial 
in patients with advanced GC and a good performance 
status after failure of fluoropyrimidines and platinum. 
In this trial (n = 202), patients were randomized in a 
2:1 ratio to receive either chemotherapy (docetaxel 
or irinotecan) or BSC. Median OS was improved 
significantly in patients treated with chemotherapy (5.3 
mo vs 3.8 mo with BSC). The efficacies of irinotecan 
and docetaxel were comparable[26].
Finally, the recently published phase Ⅲ trial 
“COUGAR-02” confirmed that docetaxel significantly 
increased OS in patients with a performance status 
of 0-2 after progression to previous platinum/
fluopyrimidine chemotherapy. In this trial, 168 patients 
were treated with active symptom control with or 
without docetaxel (75 mg/m2 in a 21-d cycle)[29]. 
Although only 23% of the patients received 6 cycles 
of docetaxel, and only 7% presented an objective 
response to docetaxel, a modest but significant benefit 
in OS (5.2 mo vs 3.6 mo, P = 0.01) was observed. 
Moreover, despite the fact that 21% of patients 
treated with docetaxel presented grade 4 toxicities, 
significantly less pain and a trend for less dysphagia 
and nausea were reported. Global quality-of-life scores 
were similar between the two groups. 
With the publication of this well-conducted, large, 
randomized trial, the benefit of docetaxel as a second-
line treatment, in terms of improvement in tumor-
related symptoms and survival, has clearly been 
established. For this reason, all patients in good 
performance status should be offered second-line 
chemotherapy.
The activities of weekly paclitaxel (80 mg/m2 on 
days 1, 8, and 15 every 4 wk) and irinotecan (150 
mg/m2 on days 1 and 15 in 28-d cycles) as second-
line treatments were determined in a recent Japanese 
randomized phase Ⅲ study in 223 patients with 
advanced GC that had progressed after fluoropyrimidine 
plus platinum chemotherapy[30]. Irinotecan was not 
superior to taxane monotherapy in terms of median PFS 
(2.3 mo vs 3.6 mo with paclitaxel, P < 0.33) and OS (8.4 
mo vs 9.5 mo, P = 0.38), and treatment-related toxicity 
was comparable in both arms. Interestingly, third-line 
chemotherapy was administered in 97 patients (89.8%) 
after paclitaxel treatment and in 80 patients (72.1%) 
after irinotecan treatment (P = 0.001). Thus, we agree 
with the author’s conclusion that both regimens are 
valid choices for second-line treatment. 
Is combination better than single-agent chemotherapy 
in second-line treatment? 
Recently, a Japanese phase Ⅲ trial conducted by the 
Tokyo Cooperative Oncology Group evaluated single-
agent (irinotecan) vs combination (irinotecan/cisplatin) 
chemotherapy as a second-line treatment in patients 
refractory to S-1-based chemotherapy[31]. Interestingly, 
the combination of cisplatin/irinotecan demonstrated 
a PFS benefit without an OS improvement. Thus, 
according to this trial, there is no evidence for a 
benefit of combination vs single-agent chemotherapy 
in second-line treatment.
TARGETED THERAPIES 
Approximately 20% of GC are characterized by 
overexpression or/and amplification of the HER2 gene. 
HER2 overexpression is more common in intestinal GC 
than diffuse GC, and more common in GEJ GC than 
distal GC. Currently, the prognostic value of HER2 in 
GC is controversial[32]. Combining chemotherapy with 
trastuzumab results in a significant improvement in 
survival in HER2-positive GC. 
In the international phase Ⅲ “ToGA” trial, 594 
previously untreated patients with advanced HER2-
positive (either IHC 3+ or IHC 2+ and FISH+) GC 
were randomized to chemotherapy (cisplatin 80 
mg/m2 on day 1 and either capecitabine 1000 mg/
m2 twice-daily on days 1-14 every 3 wk or 5-FU 800 
mg/m2 per day continuously for 3 wk) with or without 
trastuzumab (8 mg/kg loading dose, followed by 6 
mg/kg every 3 wk). Compared with chemotherapy 
alone, the combination of chemotherapy plus tras-
tuzumab resulted in a statistically significant and 
clinically relevant improvement in RR and OS. The 
combination did not raise any new safety concerns; 
notably, the incidence of cardiotoxicity was equal in the 
2 arms[33]. Recently, an HRQol analysis showed that 
the time to deterioration of HRQoL was prolonged in 
the combination arm[33,34].
Up to now, this is the only prospective randomized 
phase Ⅲ trial exploring trastuzumab in combination 
with chemotherapy in GC, although phase Ⅱ 
data with XELOX and in combination with S-1 and 
cisplatin have shown interesting clinical activities[35,36]. 
Therefore, the benefit of trastuzumab in combination 
with other chemotherapeutic regimens needs further 
investigation. A non-interventional register studying 
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the addition of trastuzumab to different first-line 
chemotherapies found comparable results in terms 
of median PFS (6.8 mo) for other chemotherapy-
trastuzumab combinations, although the final 
results are pending. Importantly, pharmacokinetic 
data suggested that the above-mentioned dose of 
trastuzumab might not be optimal in combination 
with capecitabine and cisplatin. Therefore, a 
currently ongoing phase Ⅲ trial named HELOISE 
(NCT 01450696) is exploring two different doses 
of trastuzumab (8 mg/kg loading dose, followed by 
6 mg/kg or 10 mg/kg every 3 wk) in combination 
with cisplatin (80 mg/m2 on day 1) and capecitabine 
(800 mg/m2 twice-daily on days 1-14). Furthermore, 
the clinical value of the continuation of trastuzumab 
beyond first progression - a strategy with proven 
value in HER2-positive breast cancer - needs to be 
defined[37]. 
Second-line treatment for HER2-positive GC
Lapatinib is a small molecule TKI that binds reversibly 
to EGFR-1 and EGFR-2 (HER2) and blocks the activation 
of downstream second messengers. Lapatinib is 
approved for second-line treatment of HER2-positive 
advanced breast cancer[38].
The phase Ⅲ clinical trial, “TyTAN”, evaluated the 
efficacy of lapatinib in combination with paclitaxel in 
the second-line setting in Asian patients with HER2-
positive advanced GC. A total of 261 HER2-positive 
(by FISH) patients were randomized to lapatinib plus 
chemotherapy vs chemotherapy alone[39]. According to 
the results of this trial, the overall RR was significantly 
higher in patients treated with lapatinib, but median 
PFS and OS rates were unchanged. However, in 
subgroup analyses, patients with an IHC score of 3+ 
and patients younger than 60 years benefited from the 
addition of lapatinib to paclitaxel.
The limited efficacy of lapatinib was confirmed in 
the first-line setting for GC in the phase Ⅲ “LOGIC” 
trial, which investigated the activity of lapatinib 
in combination with capecitabine/oxaliplatin and 
demonstrated a non-significant prolongation of OS[40]. 
Future perspectives for HER2-positive GC
Currently, pertuzumab, a monoclonal antibody that 
binds to the dimerization domain of the HER2/HER3 
receptors, is being investigated in GC. In HER2-
positive metastatic breast cancer, a recently published 
phase Ⅲ trial comparing docetaxel in combination 
with trastuzumab and either pertuzumab or placebo 
demonstrated an OS benefit of 16 mo (!) for patients 
treated with pertuzumab, without significant differences 
in toxicity, especially cardiac toxicity[41]. Preclinical data 
indicate that targeting the dimerization domain of HER2/
HER3 has antitumoral activity in GC as well, although 
the serum clearance of the antibody seems to be higher 
in this setting[42]. On the basis of a randomized phase Ⅱ
a trial (n = 30) exploring two different dose schedules 
of pertuzumab (840 mg for cycle 1 and 420 mg for 
cycles 2-6 vs 840 mg in cycles 1-6) in combination 
with chemotherapy, the dose of 840 mg pertuzumab 
was selected for the ongoing international randomized 
phase Ⅲ “JACOB” trial (NCT 01774786). This trial is 
exploring the role of pertuzumab, in combination with 
trastuzumab and chemotherapy, in advanced GC. Of 
note, RRs for patients treated with pertuzumab, in 
combination with trastuzumab and chemotherapy, 
were 86% and 55% for the two doses in the above-
mentioned phase Ⅱa trial[43]. 
In analogy to the “EMILIA” trial (a randomized phase 
Ⅲ trial comparing T-DM1 (trastuzumab emtansine, an 
antibody-drug conjugate linking trastuzumab to the 
microtubule inhibitor DM1, a maytansine derivative) 
to the combination of and capecitabine) in pretreated, 
HER2-positive breast cancer, the ongoing phase Ⅲ 
GATSBY trial (NCT01641939) is evaluating T-DM1 vs 
a taxane (docetaxel or paclitaxel) in previously treated 
metastatic HER2-positive GC. 
Targeting EGFR1 in advanced GC
Despite the high (approximately 50%) rate of EGFR 
expression in GC, targeting EGFR has not proven to 
be a successful strategy, at least in unselected GC 
patients. The so-called “EXPAND” trial, which evaluated 
the addition of cetuximab to first-line chemotherapy 
with capecitabine or 5-FU in patients with advanced 
GC, failed to improve PFS or OS, independent of the 
expression of EGFR[44].
The ineffectiveness of targeting EGFR in a non-
selected population of patients with GC was confirmed 
in the phase Ⅲ REAL 3 trial. In this trial, panitumumab 
or placebo was added to first-line chemotherapy with 
EOX[45]. The study was terminated prematurely due to 
a significantly worse median OS (8.8 mo vs 11.3 mo) 
in the patients treated with EOX and panitumumab. 
Predictive biomarkers for the efficacy of panitumumab 
(mutations in KRAS, BRAF, PIK3CA or loss of PTEN 
expression) could not be identified.
Nevertheless, in patients with advanced NSCLC, 
high EGFR expression (IHC score > 200) was found 
to be a predictor of survival for patients treated with 
the combination of first-line chemotherapy plus 
cetuximab[46]. Currently, data for patients with GC and 
high tumor EGFR expression is pending. However, 
a small randomized phase Ⅱ trial demonstrated 
that in a subgroup of patients with IHC 2+/3+ 
EGFR metastatic GC, adding the EGFR monoclonal 
antibody nimotuzumab to irinotecan might improve 
the antitumoral activity[47]. Based on these results, 
a randomized phase Ⅲ trial (ENRICH trial, NCT 
01813253) investigating this combination as a second-
line regimen in EGFR-overexpressing GC is ongoing in 
Japan and South Korea.
Role of angiogenesis
Angiogenesis has become an important target in the 
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treatment of several solid tumors. In GC, increased 
VEGF-A expression has been correlated with a poor 
prognosis. Therefore, several studies tried to explore 
the role of anti-angiogenic therapies in this context[48,49].
Results from the international phase Ⅲ “AVAGAST” 
study, which assessed the benefit of adding beva-
cizumab, a monoclonal antibody targeting VEGF, to 
a cisplatin/capecitabine combination chemotherapy 
regimen[50], showed only a modest improvement 
in PFS (6.7 mo vs 5.3 mo), without an OS benefit 
(12.1 mo vs 10.1 mo). Nevertheless, in an unplanned 
subgroup analysis, OS was significantly improved 
in non-Asian patients, in patients with the diffuse 
subtype, and in patients with distal GC. Furthermore, 
recent data demonstrated a clear benefit of targeting 
angiogenesis in the second-line setting. In contrast 
to bevacizumab, ramucirumab is an Ig1 monoclonal 
antibody and antagonist of the VEGF receptor 2, 
blocking the binding of VEGF A, C and D. The phase Ⅲ 
“REGARD” trial evaluated ramucirumab monotherapy 
(8 mg/kg every 15 d) vs placebo in 355 patients[51] 
after failure of first-line chemotherapy. Ramucirumab 
increased median OS by 37% (5.2 mo vs 3.8 mo, HR 
= 0.776, 95%CI: 0.603-0.998) as well as PFS (2.1 
mo vs 1.3 mo, HR = 0.483, 95%CI: 0.376-0.620). 
Importantly, ramucirumab was well-tolerated, with 
hypertension (8% with grade ≥ 3) being the most 
important side effect. Rates of grade > 3 arterial and 
venous thromboembolism were 1% vs 0% and 1% vs 
4%, respectively, in the patient groups[43].
The activity of ramucirumab, in combination 
with chemotherapy, in second-line treatment of GC 
was confirmed by the phase Ⅲ “RAINBOW” trial. In 
this study, 665 patients were randomized to receive 
paclitaxel (80 mg/m2 on days 1, 8 and 15), with 
or without ramucirumab (8 mg/kg every 15 d). 
Patients treated with ramucirumab had significant 
improvements in median OS (9.6 mo vs 7.4 mo, HR = 
0.807, 95%CI: 0.678-0.962), PFS (4.4 mo vs 2.9 mo, 
HR = 0.635, 95%CI: 0.539-0.752, P < 0.0001) and 
RR (28% vs 54%, P = 0.0001)[52]. 
These proof-of concept trials for the inhibition 
of angiogenesis in metastatic GC were confirmed 
by another phase Ⅲ trial evaluating apatinib, the 
oral VEGR-2 tyrosine kinase inhibitor, after failure 
of second-line chemotherapy[53]. In this study, 293 
heavily pretreated Chinese patients were randomized 
to apatinib (850 mg/d) vs placebo. Although median 
PFS (as assessed by the investigators) was 2.6 mo 
in the experimental group and 1.8 mo in the placebo 
group (HR = 0.44), median OS was 6.5 and 4.7 mo, 
respectively (HR = 0.71). However, objective RRs were 
3% vs 0%. Furthermore, 9% of the patients treated 
with apatinib developed a hand-foot syndrome of 
grade 3/4. 
These data confirm the importance of angiogenesis 
as a pathway and support further development of anti-
angiogenic treatments for GC. 
FUTURE PERSPECTIVES 
For the moment, several novel targets are under 
investigation (Table 1). For example, the PI3K/AKT/
mTOR pathway plays a crucial role in multiple cellular 
functions including proliferation, angiogenesis and cell 
growth. The results of a phase Ⅲ trial, GRANITE-1, 
were recently released. The study compared everolimus, 
a mTOR inhibitor, to placebo in pretreated advanced 
GC and did not show an improvement in OS (5.4 mo 
vs 4.3 mo)[54]. 
Hepatocyte growth factor (HGF), as well as its 
receptor mesenchymal epithelial transition factor (MET), 
play key roles in GC[55,56]. Rilotumumab, a fully human 
IgG2 monoclonal antibody against HGF, demonstrated 
promising preliminary results in combination with EOX 
in a randomized phase Ⅱ study[57]. Furthermore, recent 
data showed that MET-positive patients respond better 
to the combination of rilotumumab and ECX than do 
MET-negative patients[58]. Due to the increased toxicity 
and treatment-related deaths in the combination 
group in RILOMET-1, all clinical trials investigating the 
role of rilotumumab in GC - including the phase Ⅲ 
RILOMET-1 (with ECX) and RILOMET-2 (with cisplatin 
and capecitabine) trials - have been terminated. 
Results of the RILOMET-1 trial have been presented 
at the ASCO 2015 Annual Meeting; both OS and 
PFS were statistically worse in the rilotumumab 
arm, independent of MET expression[59]. In addition, 
preliminary results of a phase Ⅱ trial evaluating 
onartuzumab, another monoclonal antibody designed 
specifically to target the MET receptor, failed to show 
a PFS benefit when added to mFOLFOX in a first-line 
setting in patients with HER2-negative metastatic 
GC[60].
Cancer immunotherapy has seen major advances 
in the last 10 years. Checkpoint inhibitors have become 
the cornerstone in the treatment of melanoma and - 
compared with docetaxel - demonstrated a significant 
improvement in OS in a randomized phase Ⅲ trial in 
NSCLC[61]. Early results of “KEYNOTE-012” a phase 
Ib trial evaluating pembrolizumab, a humanized anti-
PD-1 monoclonal antibody, were initially presented at 
the 2015 ASCO Gastrointestinal Cancers Symposium, 
and update data was reported at the ASCO 2015 
Annual Meeting. In this trial, 39 chemotherapy-
refractory patients with advanced GC, good PS and 
either distinctive stromal or ≥ 1% of tumor nest cell 
PD-L1-staining were treated with pembrolizumab 
(10 mg/kg every 2 wk) until complete response, 
disease progression, or unacceptable toxicity[62]. With 
a 22.2% objective RR, as assessed by central review 
after a median follow-up of 8.8 mo, pembrolizumab 
demonstrated promising anticancer activity in this 
heavily pretreated population. Thirteen patients (33%) 
remain on therapy. A total of 53.1% of patients with 
measurable disease displayed some degree of tumor 
shrinkage from baseline. At 6 mo, 69% of patients 
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remained alive, and the median OS was 11.4 mo[63].
The incidence of side effects was low, and only 3 
patients presented toxicities grade ≥ 3. Further 
trials with different checkpoint inhibitors in GC are in 
preparation. 
This trial is one example whereby identifying 
molecular subtypes of GC may help to better 
understand this heterogeneous cancer, leading to 
the development of novel therapeutic strategies. The 
discovery of key driver genes in these subgroups 
(such as TP53 in microsatellite stable tumors and 
ARID1A in EBV-positive tumors) reveals further 
potential molecular biomarkers, and the development 
of other targeted therapeutic strategies is ongoing. 
For example, JAK2 amplification was seen in 6% of 
EBV-positive tumors, leading to the activation of the 
JAK/STAT and PI3K/Akt/mTOR pathways, opening new 
perspectives for the design of clinical trials with JAK2 
inhibitors.
CONCLUSION
The treatment of advanced GC remains a major 
challenge, and many questions remain unresolved. 
Although significant progress has been made in recent 
years by routinely treating patients with second- and 
further lines of chemotherapy, as well as integrating 
HER2-targeting drugs and ramucirumab in the routine 
care of patients with advanced GC, many phase Ⅲ 
trials (e.g., those with EGFR inhibitors or everolimus) 
have had negative results, and others (e.g., RILOMET) 
had to be closed prematurely due to unexpected 
toxicity. Among the unresolved issues is whether 
some subgroups of patients benefit more than others 
from certain chemotherapy regimens (e.g., doublet vs 
triplet regimens). 
Furthermore, the optimal duration of combination 
chemotherapy remains unclear: should we continue 
until progression, or just continue with maintenance 
therapy? Moreover, valid biomarkers other than HER2 
are required to select patients for clinical trials in 
molecularly-defined subtypes of GC. The results of the 
KEYNOTE 12 trial have provided a first signal of the 
efficacy of immunotherapy in advanced GC. However, 
further trials, and especially longer follow-up, are 
necessary to validate the efficacy of immunotherapy. 
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